TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study Telmisartan and Amlodipine in Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. patients aged at least 18 years~2. diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the preceding trial.~3. failure to respond to six weeks treatment with Amlodipine 5 mg in the run-in period of the preceding trial.~Exclusion Criteria:~1. pre-menopausal women who are not surgically sterile; or are nursing or pregnant; or are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study~2. development of any medical condition in the preceding trial that in the investigator's opinion could be worsened by treatment with either Telmisartan 40 mg/Amlodipine 5 mg or Telmisartan 80 mg/Amlodipine 5 mg~3. discontinuation from the preceding trial because of any adverse event or any other reason~4. known or suspected secondary hypertension~5. mean seated Systolic Blood Pressure =\> 180 mmHg and/or mean seated Diastolic Blood Pressure =\> 120 mmHg at any visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Examine Health Effects of Daylight Exposure on Dementia Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Residents were recruited according to the trial inclusion criteria: 1) Alzheimer's disease and related dementias (ADRD) diagnosis, 2) no physical co-morbidities that precluded participation in the daily group intervention, and 3) a Mini-Mental State Exam (MMSE) score of 10 or higher~Exclusion Criteria:~* physical co-morbidities that precluded participation in the daily group intervention

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): At the 4 facilities in the control arm, participants received the usual care. During the period from 8:00 - 10:00 AM each day, the control group was taken to a similar sized area indoors (without daylight) for socialization under typical electrical lighting conditions.
- Daylight Intervention (Type: ACTIVE_COMPARATOR): At the 4 facilities in the active light intervention arm, staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Filtered Trial for Telmisartan 40mg Non-responder

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Essential hypertensive patients who satisfying non-responder criteria~2. Male or Female~3. Age 20 years or older~4. Outpatient~Exclusion Criteria:~1. Taking four or more anti-hypertensive medications~2. Secondary hypertension~3. Mean seated diastolic blood pressure (DBP) \> 114 mmHg and/or mean seated systolic blood pressure (SBP) \> 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP \< 90 mmHg at Visit 3.~4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias~5. Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV~6. History of myocardial infarction or cardiac surgery within last 6 months~7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months~8. History of unstable angina within last 3 months~9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve~10. History of stroke or transient ischemic attack within last 6 months~11. History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy~12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors~13. Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs~14. Hepatic and/or renal dysfunction~15. Diagnosed biliary atresia or cholestasis~16. Hyperkalemia~17. Dehydration~18. Sodium deficiency~19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)~20. Patients who cannot change to the restricted administration and dosage during study period~21. Pre-menopausal women who meet any one of the following 1 - 3:~    * Pregnant or possibly pregnant (1)~   * Nursing (2)~   * Desire to become pregnant during study period (3)~22. Drug or alcohol dependency~23. Complication of malignant tumour or a disease requiring immunosuppressants~24. Compliance of \< 80% or \> 120% during the run-in period~25. Receiving any investigational therapy within 3 months~26. Judged to be inappropriate by the investigator or the sub-investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: E-Cigarette Effects on Markers of Cardiovascular and Pulmonary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* able to read and write English~* no plans to quit smoking and/or e-cig use in the next month~* not using cigars/smokeless/snus tobacco \>/= 1 time per week~* having a stable pattern of current product use~* able to walk at least 2 blocks without assistance or stopping~* Specific to Exclusive Smokers:~  * smokes daily~ * \>/= 5 cigs/day for last 6 months~ * \< 3 uses E-cigs in lifetime~ * \>/= 5 ppm carbon monoxide (CO)~ * Cotinine \> 100 ng/ml~* Specific to Exclusive E-cig users:~  * \</= 2 days per month cigarette use for last 6 months~ * \>/= 5 days per week E-cig use for last 3 months~ * \</= 4 ppm CO~ * Cotinine \> 100 ng/ml~* Specific to Never-users~  * \< 100 cigarettes in a lifetime, none for \> 5 years~ * \< 3 E-cig uses in a lifetime~ * \</= 4 ppm CO~ * Cotinine \< 100 ng/ml~Exclusion Criteria:~* current use of a smoking cessation medication~* women who are pregnant or plan to get pregnant in the coming month~* women who might be pregnant~* incarcerated individuals~* history of sarcoidosis in past 5 years, or active interstitial lung/pulmonary fibrosis~* history of positive Coronavirus-19 test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Exclusive Smokers (Type: None): Smokes Daily; \>/= 5 cigarettes/day for last 6 months
- Exclusive E-Cig users (Type: None): E-cig usage \>/= 5 days/week for last 3 months
- Never users (Type: None): \< 100 cigarettes in lifetime, none for \> 5 years; \< 3 E-cig usage in lifetime

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HR-lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* documented diagnosis of asthma or COPD in accordance with guidelines~* stable condition, defined as a disease without exacerbation for at least 1 month prior to study enrolment~* mean HR in holter ECG recording of ≥ 60 bpm~Exclusion Criteria:~* disease exacerbation in previous month~* inability to understand instructions on study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ivabradine-Placebo (Type: ACTIVE_COMPARATOR): None
- Placebo-Ivabradine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bio-availability of Rectal Artesunate in Children With Severe Falciparum Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Weight ≥6 kilograms and ≤ 34 kilograms~* Severe malaria (WHO Guidelines 2013; Appendix 1)~* P. falciparum infection confirmed by Rapid Diagnostic Test (P. falciparum monoinfection or mixed infection with P. ovale or P. malariae)~* Parents or guardian signed Informed Consent~Exclusion Criteria:~* Acute diarrhoea defined as \> 3 liquid stools in the previous 24 hours~* Visible anorectal malformations or a disease of the rectum~* Known hypersensitivity to quinine or artesunate~* A documented history of an effective dose of parenteral antimalarial in the preceding 24 hours or a single dose of rectal artesunate in the previous 12 hours or a dose of an artemisinin based combination therapy in the previous 6 hours~* Co-morbidity which in the judgement of the investigator would interfere with the patient treatment or results of the study or place the subject at undue risk~* Participation in another clinical trial or earlier in the same clinical trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IR artesunate + IV artesunate (Type: EXPERIMENTAL): Patients receive 1 dose of intrarectal artesunate (10 mg/ kg b.w.) on admission and 1 dose of intravenous artesunate (2.4 mg/kg body weight) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
- IV artesunate + IR artesunate (Type: EXPERIMENTAL): Patients receive 1 dose of intravenous artesunate (2.4 mg/kg b.w) on admission and 1 dose of intrarectal artesunate (10 mg/ kg b.w.) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, as determined by a responsible and experienced physician~* Male or female between 18 and 45 years of age~* Body weight \>50 kg (110 lbs) for males or \>45 kg (100 lbs) for females, and body mass index (BMI) between 19.0 and 24.0 kg/m2~Exclusion Criteria:~* Positive result for hepatitis B, hepatitis C or HIV at screening~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities~* Positive urine drug screen and breath alcohol test at screening or prior to dosing~* Lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- TDF tablets (Type: EXPERIMENTAL): Tenofovir disoproxil fumarate tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Crossover Study of Neurally Adjusted Ventilatory Assist (NAVA) in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* preterm infants mechanically ventilated~* ventilatory set frequency is under 25~* with informed consent of their parents~Exclusion Criteria:~* major congenital anomalies~* patients without self respiratory effort~* use of sedative or anesthetic drugs~* grade III or IV intraventricular hemorrhage~* phrenic nerve palsy or insufficiency

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Weeks
- Healthy Volunteers: f

Study Arms:
- ventilator assist (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 to 75~* BMI ≥ 25.0 kg/m2~* HbA1c ≥ 8.0% and ≤ 10.5%~* Type 2 Diabetes Mellitus and on stable dose of Metformin~* Agree to conduct home-based (fasted) blood glucose testing as directed~Exclusion Criteria:~* Clinically significant abnormalities in medical history of physical exam~* Show evidence of uncorrected hypothyroidism or hyperthyroidism hormone results~* History of solid organ transplant or renal dialysis~* History of liver disease~* History of greater than 3 episodes of severe hypoglycemia within 6 months of screening~* Treatment with any other antidiabetic drug(s) other than metformin within 3 months of screening~* History of diabetic ketoacidosis~* Any other significant illness or condition that may interfere with the patient participating or completing the study~* Inability or unwillingness to comply with protocol or study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ISIS-GCGRRx - Dose Level 1 (Type: EXPERIMENTAL): ISIS-GCGRRx - Dose Level 1
- ISIS-GCGRRx - Dose Level 2 (Type: EXPERIMENTAL): ISIS-GCGRRx - Dose Level 2
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive-Behavioral Therapy in Veterans With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* outpatients with schizophrenia or schizoaffective disorder in proximity to the West Los Angeles VAMC~* at least one month since last hospitalization~* stable antipsychotic medication with persisting psychotic symptoms with at least minimal distress~* competent to sign informed consent.~Exclusion Criteria:~* in other individual psychotherapy~* presence of organic brain disease~* mental retardation~* illness that would prohibit regular attendance in therapy~* substance dependence diagnosis in the past 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive Behavioral Therapy for Psychosis (CBTp) (Type: EXPERIMENTAL): approximately 6 months of weekly individual manualized cognitive-behavioral psychotherapy for psychosis in which participants set personal goals, identify problematic/ illness-related beliefs and experiences that may interfere with achieving those goals, evaluate the data supporting those beliefs, and then modify the beliefs or behavior as warranted by the data to make progress on those goals.
- Supportive Therapy (ST) (Type: ACTIVE_COMPARATOR): approximately 6 months of weekly manualized supportive psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to the participants' lives and concerns

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral/Intramuscular B12 to Treat Cobalamin Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 65 aged patients with Cobalamin Deficiency.~* Patients give inform consent.~Exclusion Criteria:~* Treatment with B12 (1 last year)~* Neurologic or psychiatric pathologies~* Folic acid \< 2.3ng/ml ...

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oral Cobalamin (vitamin B12) (Type: EXPERIMENTAL): oral Cobalamin (vitamin B12)
- intramuscular Cobalamin (vitamin B12) (Type: EXPERIMENTAL): intramuscular Cobalamin (vitamin B12)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric subjects with perennial allergic rhinitis who satisfy all of the following main criteria:~  * Subjects having symptoms of perennial allergic rhinitis of moderate to severe degree, after the pretreatment observation period.~ * Subjects confirmed to be allergic to non-seasonal environmental antigens (e.g., house dust-mite antigen).~ * Male or female outpatients aged 5 to 15 years at the time of providing informed consent.~Exclusion Criteria:~* Subjects for whom any of the main exclusion criteria below is applicable will not be registered in this study.~  * Subjects with coexisting tuberculous disease or lower respiratory tract infection and subjects who have a nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) requiring treatment at the time of registration~ * Subjects with coexisting infections or systemic mycosis for which there are no effective antibiotics~ * Subjects with repeated epistaxis~ * Subjects who have nasal septum ulcers, nasal surgery, or nasal trauma, which have not healed~ * Subjects with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension, or other serious coexisting diseases and whose general condition is poor~ * Subjects with complication of vasomotor rhinitis or eosinophilic rhinitis.~ * Subjects with nasal conditions (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, septal deviation, etc.) which may interfere with the evaluation of the efficacy of the study drug.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Mometasone furoate nasal spray (MFNS) (50 μg spray device) (Type: EXPERIMENTAL): The dose will be as follows:~* 5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks
- MF placebo nasal spray (Type: PLACEBO_COMPARATOR): Administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SAR231893-LPS15497- Dupilumab Effect on Sleep in AD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Participants, male or female 18 years or older,~* with diagnosed chronic AD, demonstrated 1) inadequate response to topical medications, 2) expected severity of AD and 3) sleep disturbance.~* had applied skin emollients (moisturizers) at least 7 days before screening.~* had applied medium potency topical corticosteroids (TCS) on all active AD lesions at least 7 days before screening.~* willed and able to comply with all clinic visits and study-related procedures.~* provided signed informed consent.~Exclusion criteria:~Participants excluded from the study:~* with known hypersensitivity to Dupixent, clinical depression, drug abuse history, sleep problems not related to AD, irregular sleep pattern, active/acute infections, severe medical conditions, laboratory abnormalities, any condition that might present unreasonable risk to participants or interfered with study assessment, or any severe concomitant illness(es) that would adversely affect the participant's participation in the study, and contraindications of topical corticosteroids.~* at Baseline, presence of any conditions listed as criteria for study drug discontinuation.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dupilumab/Dupilumab (Type: EXPERIMENTAL): Participants received dupilumab 600 milligrams (mg) (loading dose) injection subcutaneously (SC) on Day 1 followed by dupilumab 300 mg injection SC every 2 weeks (q2w) up to Week 10 in the double-blind (DB) period of 12 weeks. After completion of DB period, participants entered in the open-label extension (OLE) period (Week 12 to 24) and continued to receive dupilumab 300 mg injection SC q2w from Week 12 up to Week 22.
- Placebo/Dupilumab (Type: PLACEBO_COMPARATOR): Participants received placebo matching to dupilumab injection SC on Day 1 then followed by placebo injection SC q2w up to Week 10 in the DB period of 12 weeks. After completion of DB period, participants entered in the OLE period (Week 12 to 24) and received dupilumab 600 mg (loading dose) at Week 12 followed by dupilumab 300 mg injection SC q2w up to Week 22.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete